SCHEMBL21292891

SCHEMBL21292891

CC(Cc1c[nH]c2ccc(Cl)cc12)NC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.61
MTNR1A P48039 1/20 0.55
MTNR1B P49286 1/20 0.55
GFER P55789 1/20 0.53
HSD17B10 Q99714 1/20 0.53
GPR84 Q9NQS5 1/20 0.52
TSHR P16473 1/20 0.52
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP14 P50281 1/20 0.50
F7 P08709 1/20 0.50
F3 P13726 1/20 0.50
NR3C1 P04150 2/20 0.49
NR3C2 P08235 1/20 0.49
SNCA P37840 1/20 0.48
ITGB2 P05107 1/20 0.48
ICAM1 P05362 1/20 0.48
ITGAL P20701 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21292889 1.00 HTR2A (0.61) HTR2AMTNR1AMTNR1BGFERHSD17B10
SCHEMBL21292855 0.85 HTR2A (0.61) HTR2AMTNR1AMTNR1BGPR84TSHR
SCHEMBL20242715 0.85 HTR2A (0.61) HTR2AMTNR1AMTNR1BGPR84TSHR
SCHEMBL20425196 0.85 HTR2A (0.61) HTR2AMTNR1AMTNR1BGPR84TSHR
SCHEMBL21310063 0.83 HTR2A (0.54) HTR2AMTNR1AMTNR1BGFERHSD17B10
SCHEMBL30180785 0.83 HTR2A (0.54) HTR2AMTNR1AMTNR1BGFERHSD17B10
SCHEMBL28507315 0.83 HTR2A (0.54) HTR2AMTNR1AMTNR1BGFERHSD17B10
SCHEMBL27220752 0.82 HTR2B (0.63) HTR2AMTNR1AMTNR1BHSD17B10GPR84
SCHEMBL21292933 0.82 HTR2B (0.63) HTR2AMTNR1AMTNR1BHSD17B10GPR84
SCHEMBL21292935 0.82 HTR2B (0.63) HTR2AMTNR1AMTNR1BHSD17B10GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 HTR2A 3134/4885MTNR1A 2332/4885MTNR1B 1738/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 HTR2A 3059/4885MTNR1A 2360/4885MTNR1B 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.